Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Markou (Pikermi, Greece), S. Tryfon (Thessaloniki, Greece), P. Steiropoulos (Alexandroupolis, Greece), A. Ginis (Pikermi, Greece), A. Athanassiou (Pikermi, Greece), N. Grekas (Pikermi, Greece). Evaluation of the clinical efficacy of the fluticasone-salmeterol fixed dose combination (FDC) in Greek patients with Chronic Obstructive Pulmonary Disease-AEOLOS study. 3245

Member's Comments

No comment yet.

Related content which might interest you: Cardiovascular safety of fixed dose combination long acting bronchodilators in stable patients with Chronic Obstructive Pulmonary Disease. Source: International Congress 2018 – Cardiovascular morbidities in COPD Year: 2018 Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 One year change in health status in patients with stable Chronic Obstructive Pulmonary Disease (COPD) under long-acting bronchodilators treatment Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Microbiome Use to Stratify Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (MUSIC) trial: baseline data and impact of inhaled corticosteroid withdrawal in severe COPD with frequent exacerbations Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020 Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Once-daily tiotropium and olodaterol fixed-dose combination via the respimat improves outcomes vs mono-components in COPD in two 1-year studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Effectiveness of indacaterol with or without tiotropium in patients with moderate or severe chronic obstructive pulmonary disease (COPD) - the GOLDEN II study Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care Year: 2014 Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Home management of severe Chronic Obstructive Pulmonary Disease (COPD): results from a randomized controlled study in Italy Source: International Congress 2019 – Clinical implications of COPD management Year: 2019 Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Late Breaking Abstract - Inhaled corticosteroids (ICS), blood eosinophils (EOS), and FEV1 decline in patients with Chronic Obstructive Pulmonary Disease in a large UK primary healthcare setting Source: International Congress 2018 – Epidemiology of COPD : from exarcebations and comorbidities to asthma-COPD overlap syndrome (ACOS) Year: 2018 Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Sing-a-Lung: Group singing as training modality in pulmonary rehabilitation for patients with Chronic Obstructive Pulmonary Disease (COPD): A multicenter, cluster-randomised, non-inferiority controlled trial Source: Virtual Congress 2020 – Best abstracts in the field of pulmonary rehabilitation Year: 2020